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Abstract: Post-operative hyperglycaemia is important with regard to outcomes of surgical operations. It affects post-
operative morbidity, length of hospital stay, and mortality. Poor peri-operative blood glucose control leads to a higher risk of 
post-operative complication. Insulin resistance as a cause of post-operative hyperglycaemia has been blamed for some time. 
Nitric Oxide (NO) is produced by nitric oxide synthase (NOS) isoenzymes. Inducible nitric oxide synthase (iNOS) is not a 
normal cellular constitute. It is expressed by cytokines and non-cytokines e.g. fasting, trauma, intravenous glucose, and lipid 
infusion, which are encountered in surgical operations.  Review of current published data on postoperative hyperglycaemia 
was completed. Our studies and others were explored for the possible role of NO in this scenario. Induction and expression of 
iNOS enzyme in pancreatic islet cells is included in the chaotic postoperative blood glucose control. The high concentrations of 
iNOS derived NO are toxic to pancreatic  -cells and may inhibit insulin secretion postoperatively. Hence, current peri-operative 
management is questionable regarding post-operative hyperglycaemia and necessitates development of a new strategy. 
Key words: NO, glucotoxicity, lipotoxicity, post-operative hyperglycaemia, pancreatic islets. 
 
Post-operative hyperglycaemia: A real problem 
Post-traumatic hyperglycaemia is commonly 
encountered after surgery and in patients treated in 
intensive care units (ICU). It carries a higher risk for post-
operative complications, prolonged recovery periods, and 
increased length of stay (LOS) [1,2]. 
 
Poor post-operative blood glucose control in diabetic [1] 
and non-diabetic patients [2] leads to a higher risk of 
complications. Many studies (3, 4) blame insulin resistance 
as a cause for post-operative hyperglycaemia. Cytokines 
[5,6], fasting [7,8], peri-operative feeding [9,10] and 
immobilization were reported to lead to insulin resistance. 
Different regimens postulated to overcome the outcome of 
elective operations [11,12]. Emergency traumatic surgery 
in conditions e.g. high velocity missile injury and traffic 
accidents carry an additional risk for post-operative 
hyperglycaemia because of double trauma. 
 
To decrease post-operative morbidity and mortality, it is 
essential to explore the molecular mechanism of post-
operative hyperglycaemia and its relation to trauma. 
Pancreatic function during trauma has not been 
thoroughly studied. It is very important to comprehend 
post-operative hyperglycaemia and evaluate peri-operative 
management to improve surgical outcomes. 
 
Review of currently published data on post-operative 
hyperglycaemia was conducted and the role of nitric oxide 
in this scenario was investigated. 
 
Nitric oxide and nitric oxide synthase system 
Nitric oxide (NO) was described in 1989. NO is the 
smallest synthetic molecule. It is produced by a family of 
enzymes known as nitric oxide synthase (NOS) in almost 
all mammalian cells e.g. vascular endothelium, neurons of 
the central and enteric nervous system, and cells of the 
immune system [13,14]. NO is a free radical and an 
extremely reactive gas [15]. It has a short half life of 
about 10 seconds. It acts as a signalling molecule, 
neurotransmitter, and macrophage mediated immunity 
that can heal or kill. Under conditions of high NO 
production, a number of enzymes can be inhibited by NO-
enzyme interaction [16-18]. 
 
According to their expression, activity, and dependence 
on calcium, NOS isoenzymes are divided into 2 major 
functional classes: 
• Constitutive nitric oxide synthase (cNOS); ncNOS, 
ecNOS 
• Inducible nitric oxide synthase (iNOS). 
 
Nitric oxide and insulin secretion 
cNOS and iNOS can be expressed and/or induced by 
different stimuli in various tissue including pancreatic  -
cell [17,19-24]. ncNOS derived NO is recognized as an 
important signalling molecule in a variety of cellular 
processes e.g. insulin secretion [19,21,22,24]. 
 
Our laboratory [23,27,29-30] and others [25,31-33] 
presented biochemical and immuno-cytochemical evidence 
for occurrence of ncNOS in mouse and rat pancreatic  -
cells. When cNOS is activated, it produces a pulsatile low 
amount of NO for a short period of time [29,31,34]. 
Although the effect of ncNOS derived NO on insulin 
secretion is highly controversial, the results from rat and 
mouse pancreatic islets suggests that it acts as a negative 
modulator for glucose-stimulated insulin secretion (GSIS) 
[27,29].
iNOS is not a normal cellular constituent and can only 
be expressed in  pathophysiological conditions in a 
response to inflammatory cytokines e.g. IL-1 , TNF- , and 
lipopolysaccharide. Under such conditions, pancreatic  -
cells produce huge amounts of NO in a more sustained 
manner [27,34-36] through induction of iNOS, comparing 
to the cNOS isoforms [15,37-38]. Non-cytokine induction 
of iNOS in pancreatic islets has also been reported. One 
hour in vitro incubation of healthy rat and mouse islets 
with high glucose concentrations [10-20 mmol/L) induced 
iNOS and ncNOS [27,30,34]. However, the activation of 
ncNOS was rapid, within minutes. It is at least in part, 
associated with the glucose-stimulated influx of 
extracellular Ca2+ into  -cells [27,33]. Glucose activation 
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of iNOS was slower and detectable after approximately 60 
minutes [27]. The mechanism behind glucose-stimulated 
iNOS expression and activity is poorly understood. It has 
been suggested that glucose metabolism generates 
NADPH through the pentose shunt, which is an important 
stimulus in IL-1  induction of iNOS [39,40]. NADPH is an 
obligatory substrate for iNOS synthesis of NO [20-21]. 
This is of great interest since high amounts of iNOS 
derived NO is detrimental to  -cells [38-39]. Moreover, we 
showed that 24 hour intravenous (IV) glucose 
administration induced marked expression and activity of 
islets iNOS [41]. 
 
 
Figure1  Simple scheme illustrating the possible mechanisms for 
the toxic effects of NOS-derived NO on   -cell function 
 
The inhibitory effect of increased NO production on 
insulin secretion, due to either enhanced activity of cNOS 
(physiological) or induction of iNOS (inflammatory 
condition) [29,38,42]. NO is widely accepted as a mediator 
of  -cell dysfunction and apoptosis [29,30,34,43-45]. A 
clear role of iNOS in the pathogenethesis of type 1 
diabetes mellitus   has been reported [38-39].  
 
In addition, the extremely low level of NO metabolizing 
enzymes, e.g. catalase and glutathione peroxidase, makes 
pancreatic  -cells extremely susceptible to high levels of 
intracellular NO (46). High concentration of NO may 
interact with vital sites in the  -cell such as Kreb’s cycle 
enzyme aconitase [47], ion channels [48], or other 
enzymes of importance for  -cell function [30,34,43,48] 
(Figure 1). Indeed, several studies demonstrated that 
inhibition of NOS isoenzymes activity by specific inhibitors 
was accompanied by enhanced GSIS, both in vitro and in 
vivo [27,29,30,34].  
 
Initial inhibition of insulin release is exerted by ncNOS-




Chronic hyperglycaemia is detrimental to pancreatic  -
cells. It could be implicated in the pathogenesis of type 2 
diabetes mellitus (DM) in a process called glucotoxicity 
[50-51].  
We showed that the route of nutrient administration is 
important in pancreatic function by both biochemical and 
immuno-cytochemical evidences. Hyperglycaemia induced 
by IV glucose administration, or hyperlipidemia by IV 
intralipid infusion, caused marked induction and 
expression of iNOS in rat  -cells [41]. This is consistent 
with previous reports, that plasma insulin response was 
much greater following glucose ingestion than IV glucose 
administration despite an equivalent increase in plasma 
glucose concentration. This is explained by the release of 
incretin hormones from endocrine cells in the 
gastrointestinal tract e.g. glucagon-like peptide-1 (GLP-1) 
[52-53]. The expression of iNOS after IV infusion of 
glucose could be explained by suppression of release of 
GLP-1 and glucose-dependent insulinotropic polypeptide 
(GIP) whose secretion is dependant upon ingestion of 
carbohydrates (for GLP-1) or FFA (for GIP).   
 
The relative importance of glucotoxicity versus 
lipotoxicity in inducing  -cell dysfunction and apoptosis 
remains controversial. Although it has been reported that 
lipotoxicity alone will not affect  -cell function without 
signs of glucotoxicity [54], we showed that glucose or 
intralipid infusion for 24h induced marked expression and 
activity of iNOS [41]. This is in line with results of cultured 
cell lines exposed to high glucose or FFA for 24-48 hours 
[55-56]. In this context, it is conceivable that iNOS derived 
NO might be a contributing factor in this process [55]. 
 
Furthermore, IV infusion of nutrients is commonly 
prescribed as an important treatment model both pre- and 
post-operatively [6,57], in burn patients,   and in some 
patients as a life long treatment when they can not take 
oral food.  If IV nutrients induce NO-production in human 
 -cells, this may explains post-operative hyperglycaemia 
to some degree. 
 
Lipotoxicity 
Long term Total Parenteral Nutrition (TPN) in rats for 10 
days resulted in increased iNOS and decreased ncNOS 
activity in pancreatic islets [30,34]. Infusion of lipids for 24 
hours induced suppression of insulin secretion [41]. This is 
in agreement with previous studies [30,34,58]. Although 
the induction of iNOS could not account entirely for 
alteration in  -cell survival, it might negatively modulate 
the secretory function of  -cells. In addition, long term 
exposure of  -cells to FFA resulted in a marked production 
of reactive oxygen species e.g. superoxide anion (O-2) 
[59]. Combination of NO and O-2 resulted in the formation 
of peroxynitrite, which is a powerful oxidant and cytotoxic 
molecule. The increase in NO, O-2 and peroxinitrite 
concentrations were positively correlated with 
mitochondrial and DNA damage in  -cells [44]. It has been 
reported that an increased plasma FFA obtained by IV 
infusion of lipids resulted in decreased plasma levels of 
glucagon in humans [60]. The suppression of insulin 
secretion during TPN could partly be due to the absence of 
incretin hormone which may be normalized by injection of 
GLP-1 [61].  
 
Fasting and pancreatic function 
Cyclic AMP is a potent inhibitor of islet’s NOS activity 
[24,26,30,34]. It is markedly suppressed in islets isolated 
from fasting mice and rats. Besides, GSIS was markedly 
impaired in islets isolated from fasting mice, and 
associated with a decreased production of CO and HO-2 
expression. Hence two potent inhibitors of islet NO 
production; CO and cyclic AMP, were markedly suppressed 
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in islets isolated from fasting mice and rats. This may 
explain the increased iNOS activity in  -cells and 
suppression of insulin secretion in these animals. 
 
Taken together, decreased CO production and increased 
iNOS-derived NO production is associated with a diabetic 
condition in islets  -cells [62]. 
 
Preoperative fasting or IV glucose infusion for 24 hours 
induced strong expression and activity of iNOS in rat 
pancreatic islets post-operatively (data not published), 
which was stronger than those seen in rats that received 
preoperative oral glucose or were freely fed. This is of 
significant clinical importance if the same thing happens in 
human pancreatic islets. Since, preoperative fasting and/or 
post-operative IV glucose infusions are applied in surgical 
patients, especially in abdominal operations. Hence both 
fasting and IV glucose administration play a role, at least 
partly, in suppression of insulin secretion and induction of 
post-operative hyperglycaemia. Although post-operative 
insulin resistance is still blamed, fasting and IV glucose 
may act as contributors to insulin suppression by inducing 
post-operative hyperglycaemia, which needs further study 
in humans. 
 
Trauma and  -cell function 
Trauma-induced iNOS expression and activity has been 
noted in rat pancreatic islets [63]. During trauma, the 
body responds with a series of reactions e.g. a change in 
metabolism, to a catabolic state, and an expression of 
insulin resistance [64]. The consequence of post-operative 
insulin resistance is that patients in the post-operative 
period are in a metabolic state similar to T2DM [13]. 
Insulin resistance persists for about 2-3 weeks after 
uncomplicated elective upper abdominal surgery [65]. It 
negatively affects the post-operative recovery, 
convalescent period, and LOS.  
 
Surprisingly, in spite of insulin resistance and its role in 
post-operative hyperglycaemia, iNOS isoenzyme may be 
involved very early in the impairment of the insulin 
secretion. Hence,  -cells seem to be unable to respond 
adequately to a glucose challenge. It seems reasonable to 
assume that an improvement in the insulin secretory 
capacity of the pancreas may positively affect the post-
operative glycemic state and ultimately the outcome of 
surgery. 
 
The present findings may stir more debate in the 
explanation of post-operative hyperglycaemia. 
 
Conclusions 
1. Trauma, fasting, hyperglycaemia, hyperlipidemia and 
route of nutrient administration possibly are other factors 
contribute to post-operative hyperglycaemia.  
2.  It is recommended to investigate the molecular 
mechanism behind the pathophysiology of post-traumatic 
hyperglycaemia in human beings. The role of nitric oxide 
in this scenario should be appreciated. 
3.  New strategy should be developed regarding peri-
operative management and postoperative hyperglycaemia.  
4. A possible pharmacological target is to suppress iNOS 
activity in pancreatic islets with agents stimulating cyclic 
AMP/PKA pathway e.g. PACAP. This may be a hope to 
restore adequate insulin secretion post-operatively.  
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